Population modelling of patient responses in antidepressant studies: a stochastic approach.

This paper addresses the problem of modelling longitudinal data describing patients' responses in clinical trials. In particular, a systematic approach relying on a system theoretic paradigm is proposed to deal with contexts where limited physiopathological knowledge is available on disease, drug response, and patients' characteristics. The model relies on the notion of patient's health state which summarizes the patient's condition. In order to cope with the limited number of clinical data usually available, the paper considers a very parsimonious realization where the two state variables are the clinical endpoint and its derivative. Within a population framework, the individual response is modelled as the sum of an individual shift and the average response of subjects belonging to the same study, both described as Markovian processes and identified by empirical Bayes techniques. The proposed approach is validated with experimental data from a Phase II, flexible-dose, depression trial. The dose changes due to the flexible-dose scheme are handled as perturbations on the state. The connection between inter-individual variability and model stability is evaluated showing that the introduction of stable poles helps to describe populations whose range of individual responses does not diverge with time. In this way, good individual fittings and visual predictive checks were obtained for the clinical data. The proposed analysis provides a systematic approach to semi-mechanistic modelling when a precise knowledge of the physiological mechanisms of the disease is incomplete or missing.

[1]  J. L. Steimer,et al.  Variability in drug therapy : description, estimation, and control : a Sandoz workshop , 1985 .

[2]  J. Overall,et al.  The Brief Psychiatric Rating Scale , 1962 .

[3]  A. Miller,et al.  Lung function testing: selection of reference values and interpretative strategies. , 1992, The American review of respiratory disease.

[4]  Giuseppe De Nicolao,et al.  Nonparametric input estimation in physiological systems: Problems, methods, and case studies , 1997, Autom..

[5]  Italo Poggesi,et al.  Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity , 2009, Expert opinion on drug discovery.

[6]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[7]  An Vermeulen,et al.  Structural Models Describing Placebo Treatment Effects in Schizophrenia and Other Neuropsychiatric Disorders , 2011, Clinical pharmacokinetics.

[8]  Giuseppe De Nicolao,et al.  Nonparametric identification of population models via Gaussian processes , 2007, Autom..

[9]  R. Gomeni,et al.  Bayesian modelling and ROC analysis to predict placebo responders using clinical score measured in the initial weeks of treatment in depression trials. , 2007, British journal of clinical pharmacology.

[10]  D R Mould,et al.  Using Disease Progression Models as a Tool to Detect Drug Effect , 2007, Clinical pharmacology and therapeutics.

[11]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.

[12]  Michael Krams,et al.  Evaluation of structural models to describe the effect of placebo upon the time course of major depressive disorder , 2009, Journal of Pharmacokinetics and Pharmacodynamics.

[13]  Giuseppe De Nicolao,et al.  Bayesian Population Modeling of Phase I Dose Escalation Studies: Gaussian Process Versus Parametric Approaches , 2011, IEEE Transactions on Biomedical Engineering.

[14]  Andrew P Grieve,et al.  Implementation of a Bayesian adaptive design in a proof of concept study , 2006, Pharmaceutical statistics.

[15]  Stefano Zamuner,et al.  A PCA approach to population analysis: with application to a Phase II depression trial , 2013, Journal of Pharmacokinetics and Pharmacodynamics.

[16]  M. Hamilton A RATING SCALE FOR DEPRESSION , 1960, Journal of neurology, neurosurgery, and psychiatry.

[17]  Michael D. Smith,et al.  Adaptive Bayesian Designs for Dose-Ranging Drug Trials , 2002 .

[18]  Dennis V. Lindley,et al.  Principles of Random Walk. , 1965 .

[19]  Nonparametric AUC Estimation in Population Studies with Incomplete Sampling: A Bayesian Approach , 2004, Journal of Pharmacokinetics and Pharmacodynamics.

[20]  H. Robbins An Empirical Bayes Approach to Statistics , 1956 .

[21]  Meindert Danhof,et al.  Evaluation of treatment response in depression studies using a Bayesian parametric cure rate model. , 2008, Journal of psychiatric research.